ETR:BIO Biotest Aktiengesellschaft (BIO) Stock Price, News & Analysis €41.80 +0.20 (+0.48%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range€41.80▼€41.8050-Day Range€41.00▼€42.6052-Week Range€39.60▼€44.00VolumeN/AAverage Volume1,927 shsMarket Capitalization$827.22 millionP/E Ratio10.07Dividend Yield0.10%Price TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get Biotest Aktiengesellschaft alerts: Email Address Ad Crypto 101 MediaPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankGo here to get full details on this crypto now. About Biotest Aktiengesellschaft Stock (ETR:BIO)Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, including neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B immunoglobulins. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols, S.A.Read More BIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIO Stock News HeadlinesAugust 30, 2024 | au.finance.yahoo.comBiotest Aktiengesellschaft (BIESF)August 13, 2024 | nz.finance.yahoo.comBiotest Aktiengesellschaft (BIO3.F)September 7, 2024 | Porter & Company (Ad)The death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.August 4, 2024 | ca.finance.yahoo.comBiotest Aktiengesellschaft (BIO3.SW)August 4, 2024 | ca.finance.yahoo.comBiotest Aktiengesellschaft (BIO3D.XC)April 19, 2024 | finanznachrichten.deBiotest baut aus, während Grifols weiter mit Gotham-Schatten kämpft. Ist die Mutter die spannendere Aktie?March 10, 2024 | finance.yahoo.comBiotest Aktiengesellschaft (BIOD.XC)March 9, 2024 | benzinga.comBiotest AG's Net WorthSeptember 7, 2024 | Porter & Company (Ad)The death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.December 13, 2023 | wsj.comBiotest AG Pfd.October 5, 2023 | markets.businessinsider.comEQS-Adhoc: Biotest AG: Peter Janssen appointed new Chairman of the Board of Biotest AGOctober 5, 2023 | finanznachrichten.deEQS-Adhoc: Biotest AG: Erhöhung der EBIT PrognoseOctober 5, 2023 | markets.businessinsider.comEQS-Adhoc: Biotest AG: Increase of the EBIT guidanceMay 19, 2023 | morningstar.comBiotest AG Pfd Shs - Non-votingMay 18, 2023 | investing.comHangzhou Biotest Biotech Co Ltd (688767)April 28, 2023 | markets.businessinsider.comEQS-Adhoc: Biotest AG: Biotest and Grifols further strengthen their cooperation - EBIT forecast 2023 significantly raisedApril 22, 2023 | wsj.comHangzhou Biotest Biotech Co. Ltd. AMarch 19, 2023 | finanznachrichten.deBiotech Report: Biotest und BB Biotech behauptet, MorphoSys tiefrotSee More Headlines Receive BIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biotest Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Biotechnology Sub-IndustryMeasuring And Control Equipment Current SymbolETR:BIO CUSIPN/A CIKN/A Webwww.biotest.com Phone+49-6103-8010FaxN/AEmployees8,200Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)€4.15 Trailing P/E Ratio10.07 Forward P/E Ratio348.33 P/E GrowthN/ANet Income$164.40 million Net Margins21.04% Pretax MarginN/A Return on Equity36.16% Return on Assets8.47% Debt Debt-to-Equity Ratio116.50 Current Ratio2.45 Quick Ratio1.66 Sales & Book Value Annual Sales$781.30 million Price / Sales1.06 Cash Flow€1.35 per share Price / Cash Flow31.04 Book Value€13.26 per share Price / Book3.15Miscellaneous Outstanding Shares19,790,000Free FloatN/AMarket Cap$827.22 million OptionableNot Optionable Beta0.24 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Peter Janssen (Age 56)CEO & Chairman of the Board of Management Comp: $764kMs. Ainhoa Mendizabal Zubiaga (Age 51)Member of Management Board & CFO Comp: $570kDr. Jorg Schuttrumpf (Age 50)Chief Scientific Officer & Member of the Management Board Comp: $523kDirk Schuck (Age 46)Member of Supervisory Board Dr. Monika ButtkereitHead of Investor RelationsDr. Christina ErbHead of Corporate HRMore ExecutivesKey CompetitorsMorphoSysETR:MORMedigeneETR:MDG1GenfitEPA:GNFTShop Apotheke EuropeETR:SAEEvotecETR:EVTView All Competitors BIO Stock Analysis - Frequently Asked Questions How have BIO shares performed this year? Biotest Aktiengesellschaft's stock was trading at €42.60 at the beginning of the year. Since then, BIO shares have decreased by 1.9% and is now trading at €41.80. View the best growth stocks for 2024 here. What other stocks do shareholders of Biotest Aktiengesellschaft own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biotest Aktiengesellschaft investors own include Grifols (GRFS), CSL (CSL), BioXcel Therapeutics (BTAI) and ADMA Biologics (ADMA). This page (ETR:BIO) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biotest Aktiengesellschaft Please log in to your account or sign up in order to add this asset to your watchlist. Share Biotest Aktiengesellschaft With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.